Tissue‐resident memory T cells in immunotherapy and immune‐related adverse events by immune checkpoint inhibitor

Abstract

Tissue‐resident memory T cells (TRM) are a specialized subset of T cells that reside in tissues and provide long‐term protective immunity against pathogens that enter the body through that specific tissue. TRM cells have specific phenotype and reside preferentially in barrier tissues. Recent studies have revealed that TRM cells are the main target of immune checkpoint inhibitor immunotherapy since their role in cancer immunosurveillance. Furthermore, TRM cells also play a crucial part in pathogenesis of immune‐related adverse events (irAEs). Here, we provide a concise review of biological characteristics of TRM cells, and the major advances and recent findings regarding their involvement in immune checkpoint inhibitor immunotherapy and the corresponding irAEs.